Gnosis by Lesaffre Launches Private-Label Immune Support Supplement MenaQ7 Protect

Collaboration with Probiotical features vitamin K2 with probiotics and vitamin C in an orange-flavored stick pack.

Gnosis by Lesaffre is entering the private label sector for the first time with MenaQ7 Protect, a stick pack for daily and long-term immune support.
 
Created with Probiotical, MenaQ7 Protect offers a ready-to-market solution that contains 75 mcg of MenaQ7 Vitamin K2 as MK-7, 80 mg of vitamin C, and 1 billion cells each of three strains selected for their immune-supporting benefits: Bifidobacterium animalis subsp. lactis BS01 (LMG-P-21384), Lacticaseibacillus rhamnosus LR04 (DSM 16605), and Bifidobacterium bifidum BB10 (DSM 33678).
 
The product is available in a tangy orange flavor and may be ingested directly or added to a beverage.
 
“Probiotics function in harmony with our immune system, effectively distinguishing allies from adversaries, and play a pivotal role in shielding us against harmful pathogens,” said Vera Mogna, CEO of Probiotical. “The probiotic strains selected for MenaQ7 Protect naturally occur in the human body and work in concert with the immune system to fortify the body’s defenses.”
 
Guided by the company’s Probiotical selected strains that are able to interact with the immune system, creating a targeted approach to stimulate and fortify natural defenses.
 
“This pioneering collaboration aims to harness the synergistic potential of our premium probiotic strains and MenaQ7, offering a promising new avenue to support and bolster immune health,” said Mogna.
 
While MenaQ7 is well-known and research has demonstrated its support for bone and cardiovascular health, MenaQ7 Protect also marks the debut of Vitamin K2’s role as an immunomodulator, according to Gnosis by Lessafre.
 
In-vitro research has shown MenaQ7 delivers an anti-inflammatory effect and reduces oxidative stress in human muscle cells important for immune response.1 Further, early evidence has shown that vitamin K2 may suppress T-cell activation and proliferation, support lung health, and protect against gut dysbiosis, which helps optimize immune function.
 
“We are particularly excited about MenaQ7 Protect as it represents a foray into new areas for Gnosis, both in producing a finished product, but also shifting MenaQ7 into a new condition-specific arena,” said Philippe Caillat, global marketing director with Gnosis by Lesaffre. “Immune health remains a shared common concern all year long and consumers consistently seek products that can optimize immune function continuously, while fitting into their lifestyles. MenaQ7 Protect perfectly fits this need while offering our customers a ready-to-market solution featuring our clinically proven MenaQ7 K2.”
 
MenaQ7 Protect is being produced by Probiotical, which will be fulfilling orders. 

References

1. Adubulut AC and Schurgers LJ. Bio Life Sci Forum. 2022,12(1). 

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters